Neuren Pharmaceuticals (NEU: $19.02) announced top-line results for its phase II trial of drug candidate NNZ-2591 in 16 patients with Pitt-Hopkins Syndrome (PTHS).

At this year's AGM held recently, the chairman of Anteris Technologies (AVR: $19.05) John Seaberg said that after 45 years of working in the cardiovascular field, he has never seen a device with as much potential as the DurAVR aortic valve.

Dimerix (DXB: $0.56) announced an exclusive license agreement with Taiba to commercialise DMX-200 in seven Middle Eastern countries.

Blinklab (BB1: $0.382) which listed on the ASX last month at $0.20, may have easily gone down the VC funding route, with interest at the same time from the US venture capital sector.

Company: Blinklab

Issue Price: $0.20

Funds to be raised: $7 million

ASX code: BB1

Lead Manager: Westar Capital (not underwritten)

Offer closes: 21 March 2024

Expected listing date: 4 April 2024

Market capitalisation on listing: $20 million

Dimerix - Interim Data Assessment in Mid-March

Last month, Neuren Pharmaceuticals (NEU; $24.65) announced impressive top-line data from its Phase II trial of NNZ-2591 conducted in 18 patients with Phelan-McDermid Syndrome (PMS).

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.